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ABSTRACT

Introduction: There are many problems with current state-of-the-art protocols for
maintenance dosing of the oral anticoagulant agent warfarin used in clinical practice.
The two key challenges include lack of personalized dose adjustment and the high cost of
monitoring the efficacy of the therapy in the form of International Normalized Ratio
(INR) measurements. A new dosing algorithm based on the principles of Reinforcement
Learning (RL), specifically Q-Learning with functional policy approximation, was
created to personalize maintenance dosing of warfarin based on observed INR and to
optimize the length of time between INR measurements. This new method will help
improve patient’s INR time in therapeutic range (TTR) as well as minimize cost
associated with monitoring INR when compared to the current standard of care.
Procedure: Using the principles of Reinforcement Learning, an algorithm to control
warfarin dosing was created. The algorithm uses 9 different controllers which
correspond to 9 different levels of warfarin sensitivity. The algorithm switches between
controllers until it selects the controller that most closely resembles the individual
patient’s response, and thus the optimal dose change (
measurements (

and time between INR

are personalized for each patient, based on INR observed in the

patient. Three simulations were performed using data from 100 artificial patients,
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generated based on data from real patients, each. The first simulation that was performed
was an ideal case scenario (clean simulation where the coefficient of variance (CV) of
noise added to the model output = 0) using only the warfarin RL algorithm to prove
efficacy. The second simulation was performed using the current standard of care and a
CV = 25% to simulate intra-patient variability. The third simulation was performed
using the warfarin RL algorithm with a CV = 25%. 180 days were simulated for each
patient in each simulation and the measurements that were used to benchmark the
efficacy of the therapy were INR time in therapeutic range (TTR) and the number of INR
measurements that were taken during simulation.
Results: The first simulation yielded a mean TTR = 92.1% with a standard deviation of
4.2%, and had a mean number of INR measurements = 7.94 measurements/patient. The
second simulation yielded a mean TTR = 45.3% with a standard deviation of 16.4%, and
had a mean number of INR measurements = 12.3 measurements/patient. The third
simulation yielded a mean TTR = 51.8% with a standard deviation of 10.8%, and had a
mean number of INR measurements = 8.05 measurements/patient. A p-value <.001
suggests that there is a statistically significant difference between the 2 algorithms.
Conclusion: Results from the simulations indicate that the warfarin RL algorithm
performed better than the standard of care at keeping the patient’s INR in therapeutic
range and also reduced the number of INR measurements that were necessary. This
algorithm could help improve patient safety by increasing the patient’s INR TTR in the
presence of intra-patient variability, and also help reduce the heavy cost associated with
the therapy by minimizing the number of INR measurements that are necessary.
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I. INTRODUCTION

A. Problem Statement
There are a variety of different disease states and conditions where the use of
prophylaxis is recommended to reduce the risk of thromboembolism in patients. These
disease states and conditions include, but are not limited to, atrial fibrillation, heart valve
replacements, deep vein thrombosis (DVT), and myocardial infarction (MI) (Merli &
Tzanis, 2009). Common prophylaxes that are used in clinical practice include mechanical
methods, such as compression sleeves, and pharmaceutical methods, such as
anticoagulants.
Mechanical methods used to reduce the risk of thromboembolism include a
variety of different types of compression sleeves. Compression sleeves are used to apply
pressure to areas of poor circulation, thereby reducing blood stasis (Larkin, Mitchell, &
Petrie, 2012). There are many different types of compression sleeves used in clinical
practice including uniform compression sleeves, graduated compression sleeves, and
intermittent pneumatic sleeves. Uniform compression sleeves apply uniform pressure to
the area that they are applied and are readily available to the entire population, whereas
graduated compression sleeves vary the pressure they apply throughout the sleeve and are
typically used in hospital settings (Larkin, Mitchell, & Petrie, 2012). Intermittent
pneumatic sleeves use pressure cuffs to repeatedly inflate and deflate around the area
they are applied. These sleeves can vary the amount of pressure they apply and can also
be used to apply uniform or graduated pressure. While compression sleeves have proven
to be effective in reducing thromboembolism in conditions such as DVT and surgery
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(Morris & Woodcock, 2004; MacLellan & Fletcher, 2007; Larkin, Mitchell, & Petrie,
2012), there is no evidence to suggest that they could be effective in reducing
thromboembolic events in conditions such as atrial fibrillation and MI.
Pharmaceutical methods for reducing the risk of thromboembolic event are
typically anticoagulant drugs including injectable drugs such as heparin and oral
anticoagulant drugs such as dabigatran, rivaroxaban, and warfarin. Heparin, specifically
low molecular weight heparin, binds to antithrombin III which inactivates thrombin and
factor Xa (Chuang, Swanson, Raja, & Olson, 2001). Dabigatran is a direct thrombin
inhibitor (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012). Rivaroxaban inhibits
both free factor Xa and factor Xa (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012).
Warfarin is a vitamin K antagonist and works by inhibiting the synthesis of the Vitamin
K dependent clotting factors II, VII, IX, and X (Porter, 2010). While all of these drugs
have proven to be effective in clinical practice, there are drawbacks associated with each.
Injectable heparin can cause patient discomfort because of the need for injections, and
even when it is taken orally, it still has a higher monetary cost when compared to other
oral anti-coagulants (Looi, et al., 2013). Due to the nature of these anticoagulant drugs,
there is an increased risk of patient bleeding, and because of this, there is a need to take
precautions while using anticoagulants for therapy. Warfarin has an easy reversibility of
action when compared to other oral anticoagulants, such as dabigatran and rivaroxaban,
and due to this fact, it remains the most widely used oral anticoagulant in clinical practice
today (The International Warfarin Pharmacogenetics Consortium, 2009).
The standard for measuring the efficacy of warfarin therapy, first adopted in 1982
by the World Health Organization, is known as the International Normalized Ratio (INR)
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(Wardrop & Keeling, 2008). Many of the indications for use of warfarin therapy specify
a narrow therapeutic range of 2.0-3.0, and because of this there is a need for frequent INR
measurements to minimize the risk of bleeding (when INR is too high), or
thromboembolic event (when INR is too low) (Merli & Tzanis, 2009). The high cost
associated with warfarin therapy comes from the need for frequent INR measurements.
These costs include not only the health care expenses (such as laboratory tests,
equipment, labor, etc.), but also indirect costs such as time lost from work, travel
expenses, and many others (Chambers, Chadda, & Plumb, 2009; Harrington, Armstrong,
Nolan, & Malone, 2013; Lafata, Martin, Kaatz, & Ward, 2000).
Because of the widely adopted use of warfarin oral anticoagulant therapy, there is
a need for dosing algorithms to maintain the efficacy of the therapy while reducing the
risk for bleeding or thromboembolic events. The current standard of care for warfarin
oral anticoagulant therapy, as dictated by the American Society of Hematology, is an
expert-system type algorithm that provides no dosing personalization and also does not
explicitly optimize the monitoring frequency of the efficacy of the therapy (Cushman,
Lim, & Zakai, 2011). While there are many other warfarin dosing algorithms that seek to
improve the efficacy of warfarin therapy, including pharmacogenetic algorithms
(Carlquist & Anderson, 2011) and computerized algorithms (Grzymala-Lubanski,
Själander, Renlund, Svensson, & Själander, 2013; Dimberg, et al., 2012), these
algorithms do a poor job of accounting for intra-patient variability (Kangelaris, Bent,
Nussbaum, Garcia, & Tice, 2009) and do not explicitly optimize the monitoring
frequency, which would reduce the overall cost of the therapy. Intra-patient variability
during maintenance dosing can occur due to a variety of factors such as diet, disease
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state, and drug interactions. (Ansell, et al., 2008; White, 2010). In fact, there are
currently no warfarin dosing algorithms that optimize both the warfarin dose for an
individual patient as well as the time between INR monitoring visits.

B. Current Warfarin Dosing Methods
There are three main types of algorithms that are used in clinical practice to
manage warfarin oral anticoagulant therapy. These three main types of algorithms
include dose titration, pharmacogenetic algorithms, and computerized algorithms.
Warfarin dose titration is exemplified in the dosing protocol dictated by the American
Society of Hematology, which is the current standard of care (Cushman, Lim, & Zakai,
2011). Dose titration algorithms slowly titrate a patient’s warfarin dose until the patient’s
INR levels are within the therapeutic range, and the method of titrating a patient’s dose
until the desired effect is achieved is common practice in drug dosing even outside of the
realm of anticoagulant therapy. This can be ineffective and slow to respond in the
presence of intra-patient variability, resulting patient’s INR values being outside of the
therapeutic range (Wilson, Costantini, & Crowther, 2007).
Pharmacogenetic algorithms use pharmacogenetic information, specifically,
variations in the genes CYP2C9 and VKORC1, to select a more accurate initial warfarin
dose (Carlquist & Anderson, 2011). While pharmacogenetic algorithms have been
proven in clinical practice to minimize the effect of inter-patient variability and select a
more accurate initial warfarin dose (Carlquist & Anderson, 2011), they do nothing to
account for intra-patient variability due to external factors, which is unhelpful during a
patient’s maintenance dosing period, and also are yet to gain wide acceptance among
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physicians. The required pharmacogenetic testing to determine a patient’s genetic
variations are also costly and not part of standard clinical practice.
Computerized algorithms, exemplified by AuriculA (a Swedish national quality
registry of patients treated with warfarin), use key patient characteristics, and information
about the warfarin treatment and complications to make dose suggestions (Dimberg, et
al., 2012). These algorithms operate according to 720 rules and patient history to make
dose suggestions (Grzymala-Lubanski, Själander, Renlund, Svensson, & Själander,
2013). While these algorithms have been successful in clinical practice, they require
massive databases of patient information, and also, in the presence of high intra-patient
variability, still require manual (physician initiated) dose changes. Another issue with all
of the algorithms in clinical practice are that there are no dosing algorithms that optimize
INR measurement and dose change frequency.

C. Objective
The objective of this study was to develop a new method for dosing warfarin
based on the control technique of Reinforcement Learning (RL) that will adapt to each
patient based on feedback from the patient, and will also optimize the time between INR
measurements. This new algorithm will help minimize the effect of intra-patient
variability and reduce the number of INR measurements that are necessary. Because the
current standard of care does a poor job of accounting for intra-patient variability and
does nothing to optimize the time between INR measurements, the ultimate goal of this
work is for the new warfarin RL algorithm to increase patient’s time in the therapeutic
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range (TTR) and reduce the overall cost of therapy by optimizing the INR monitoring
frequency when compared to the current standard of care.
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II. INSTRUMENTATION AND EQUIPMENT

The equipment that was used for the creation of the warfarin RL algorithm was a
Lenovo ThinkPad Edge laptop with model number 0301-DBU. The laptop was
manufactured by Lenovo (Singapore) Pte. Ltd., and it was made in China. All coding,
calculations, and graphs were done using MATLAB 7.12.0 R2011a software created by
The MathWorks Inc., located in Natick, MA.
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III. PROCEDURE

A. Reinforcement Learning Overview
Reinforcement Learning (RL) is a control method used to control a system based
on experience. Elements of Reinforcement Learning include: Environment, which is the
system that is being affected, State, which is a measurement of the environment, Action,
which is the control input into the system, Agent, which is the governing body that takes
the action, and Reward, which identifies how well the agent is performing. This method
utilizes the Markov Decision Process (MDP) to determine the optimal action to take,
while in a given state, to achieve a desired state (Sutton & Barto, 1998). The rules
governing what action to take, while in a given state, to achieve a desired state are known
as a policy, and the goal of Reinforcement Learning is to determine the optimal policy.
One of the most popular RL methods is Q-Learning. Q- Learning is a type of
Reinforcement Learning that seeks to maximize the action-value function defined as:

(

In this equation,
learning rate, and

(

⏟

(

(

is the reward observed after performing action

(1)

in state

,

is the

is the discount factor (Sutton & Barto, 1998). The learning rate

determines how much the new learning signal will outweigh past learning signals. The
discount factor determines the significance of future rewards (
account immediate reward, and

will only take into

will seek a higher cumulative reward). The term
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⏟

(

is an estimate of the optimal future action value. If the policy is

represented as a lookup table, this can be a long and arduous process, as the whole stateaction space should preferably be explored during learning, including suboptimal actions.
Depending on the problem dimensionality, there can be a large number of possible states
and actions and the learning process may be computationally expensive.
Because of the limitations of traditional RL and Q-Learning, a method known as
Q- Learning with Linear Functional Policy Approximation can help eliminate the need
for unnecessary exploration, and simplify calculations. This method translates the state
into a set of features and actions into a set of symbolic parameters (Irodova & Sloan,
2005), represented by the equation:

(

In this equation, …

(2)

…

represent the translated set of states,

symbolic parameters, and (

is the policy. Using the Q-learning equation (1), the

following update rule for each parameter (

[

represent the

⏟

) can be derived:

(

(

]

(

(3)

In this equation, (a) represents the most recent action taken, (s) represents the most recent
state observed,

represents future action, and

represents the future state (Irodova &

Sloan, 2005). Q-Learning with Linear Functional Policy Approximation eliminates the
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need to visit many state action pairs during the learning phase, some of which may be
infeasible or even impossible.

B. Warfarin Q-Learning With Linear Policy Approximation
Q-Learning with linear functional policy approximation is the control method
used to determine the optimal dose change,
measurements,

, and the optimal time between INR

. In this work, the clinical goal of warfarin therapy is to achieve a

patient INR value of 2.5 represented by

(this value is chosen because it is the

midpoint of the warfarin therapeutic range of INR = 2.0-3.0). The control method uses
the difference between the measured INR value and
output of the system, where the desired state is for

, defined by

, as the

= 0, defined by

.

The elements of this method are detailed in FIGURE 1, and the goal of this method is for
the environment to achieve the desired state,

10

.

FIGURE 1 - Block Diagram of RL based Warfarin Dosing

The patient’s body is the environment being affected, and more specifically the
mechanisms that involve thrombus formation (Hirsh, Fuster, Ansell, & Halperin, 2003;
Porter, 2010). In this work, two different patient models are used to represent the
environment (patient), the control-relevant patient model, and the simulation model. The
control-relevant patient model is used to design the controllers and is represented as
follows:

(

(

(

In control-relevant patient response model,

(4)

represents the gain (INR increase/mg/day

of warfarin administered), t represents time (in days), and
11

represents the time constant

(time until the administered warfarin dose reaches 32% of its full pharmacodynamic
(INR) effect). This model is used for controller design because it can represent the
properties of the more complex process with sufficient accuracy, while minimizing the
number of parameters. The simulation model used for simulation is represented by the
equation:

(

In the simulation model,
administered),
and

(

(

(

( )

(5)

represents the linear gain (INR increase/mg/day of warfarin

represents the nonlinear (quadratic) gain, t represents time (in days),

represents the time constant (time until the administered warfarin dose reaches

32% of its full pharmacodynamic (INR) effect). The agent is the body that governs the
actions that are to be taken. In this work the agent is represented by the equations:

(

(

(6)

(

(

(7)

The actions, governed by the agent, are
change and

and

, where

is the dose

is the time between INR measurements. The state is represented by

the observed values

and

. These values are determined by the

equations:
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(8)

(9)

INR is the patient’s current INR value and

is the

from the

previous INR measurement. The reward is a value assigned to the action based on
whether or not the environment moves closer to the desired state,

. Here, the

equation used to assign the reward is as follows:

(

(10)

(

As the INR moves farther away from the target value,

, the reward grows

smaller, and as the INR moves closer to the target value, the reward grows larger. The
maximum reward is R = 1.

C. Reinforcement Learning Warfarin Dosing Algorithm
The Overall Reinforcement Learning warfarin dosing algorithm is separated into
2 phases:
1) Learning phase (off-line)
2) Dosing phase (on-line)
The learning phase is the design phase and uses the principles of RL to “learn” the
optimal parameter values that are implemented to calculate the proper
13

and

during the dosing phase. The dosing phase uses the optimal parameter values extracted
from the learning phase to calculate the proper

and

based on

and

observed in the individual patient.
During the learning phase, 9 different controllers are created to optimize the
warfarin dose for 9 different patient responder types. These different patient responder
types range from extremely hypo-responsive (patient has a marginal INR increase
compared to the dose administered) to extremely hyper-responsive (patient has a
significant INR increase compared to the dose administered). To create the different
controllers, the control-relevant patient response model is used. Nine different K values
are used to create 9 different controllers, and are listed as follows:

TABLE I
CONTROL REVELANT K VALUES
K
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

These values are listed in order of increasing patient responsiveness ranging from
extremely hypo-responsive (K = 0.1) to extremely hyper-responsive (K = 0.9). Three
hundred learning episodes, each 120 days in length, are performed for each value of K.
Before the first learning episode for each K value, initial values for the learned
parameters are set:

= 0, a = -1, c = 0, f = .01, h = -4, and
14

= 4. Initial values are

arbitrary as the optimal parameter values will be determined over the course of the
learning episodes. RL parameters

and , which are the discount factor and the learning

rate respectively, are also initiated before the first learning episode and have initial values
of

and

. The values of the RL parameters are determined heuristically to

help reduce simulation time. Once the parameter values and RL variables are initiated,
the first learning episode begins.
Step 1: The algorithm calculates the Q values for all of the possible

values

(-5mg/day, -4.9mg/day, -4.8mg/day…+4.8mg/day, +4.9mg/day, +5mg/day), and the
calculations are made using the equation:

( (

The

that yields the highest

The same thing is done for

(

(

(

(11)

value is selected as the optimal dose change.
, the algorithm calculates the Q values for all possible

values (1-6 weeks) using the equation:

( (

The

that yields the highest

(

(

(

(12)

is then selected, and no INR measurements

are made until the selected number of weeks has passed. Step 2: The new

and

are simulated using the control-relevant patient model, with the addition of
random noise to compensate for external factors. A reward is then determined based on
the difference between the most recent INR measurement and the target INR as governed
15

by equation (10). Step 3: The reward is then used to calculate value functions for both
and

using the equations:

In these equations,
(
parameters

( ⏟

(

)

(13)

( ⏟

(

)

(14)

(

and

are estimates of optimal future values. Step 4: The
, a, c, f, h, and

are then updated based on the value functions following

the form listed in equation (3). The update equations are described as follows:

(

(

(15)

(

(

(16)

(

(

(17)

(

(

(18)
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(

(

(19)

= 0 remains constant.
Steps 1-4 are repeated until the length of the simulation meets or exceeds 120 days
(

), and once this occurs, the learning episode is finished. The learning rate is

then reduced using the equation:
(

(20)

Once the learning rate is updated, the learning episode is completed, and a new learning
episode begins. Each new learning episode exploits the previously learned parameter
values

, a, c, f, h, and

, so that they are continuously updated during each learning

episode. When all 300 learning episodes are completed, the learned optimal parameter
values

, a, c, f, h, and

are extracted.

The Dosing Phase can begin once the learning phase is complete. During the
initiation of dosing, an initial dose of 5mg/day of warfarin is given to the patient.
Patient’s INR measurements are taken on a weekly basis (days 7, 14, and 21), and after
the measurement is taken, a new dose is determined by the algorithm and administered to
the patient until it is time for the next INR measurement. To adjust the dose, a controlrelevant K value is estimated based on the most recent dose using the equation:

(21)

The K value from table 1 that is closest to the calculated

value is then selected as the

control-relevant K value. The value of 1.5 is used in the first equation because that is the
17

difference between the patient’s initial INR value (1) and the target INR value. Once the
control-relevant K value is determined, the parameters associated with that controlrelevant K value,

and

are used to determine the new dose:

(22)

In this equation,

is the most recent dose given to the patient before the INR

measurement. The calculated new dose is then given to the patient until the next INR
measurement, and this process is repeated on day 7, 14, and 21 (initiation phase). After
day 21 (maintenance phase),

is determined by the equation (7). After day 21, INR

is only measured when the algorithm suggests. For maintenance dosing, the patient’s
INR is measured when
new Dose and

suggests, the control-relevant K value is estimated, and the

are calculated.

To prove the efficacy of the new RL warfarin algorithm, three simulations were
performed on each of 100 artificial patients (with varying warfarin responses), and each
patient was simulated for 180 days of therapy. The first simulation was performed as an
ideal case scenario (random noise with CV = 0%) for verification of the RL warfarin
algorithm in the presence of no intra-patient variability. It is, however, impossible to
eliminate intra-patient variability in a real world scenario, so two more simulations were
performed to compare the industry standard of care to the RL warfarin algorithm. The
second simulation was performed following the guidelines for dosing and INR
measurements stipulated in the current standard of care, and a CV = 25% was used to
simulate extreme intra-patient variability. The third simulation was performed following

18
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guidelines stipulated by the RL warfarin algorithm, and this simulation also used a CV =
25% to simulate extreme intra-patient variability. Simulations two and three were then
used to compare the industry standard of care to the RL warfarin algorithm using %TTR
(time in therapeutic range) and the number of INR measurements as performance criteria.
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VI. RESULTS AND DISCUSSION

All simulations, calculations, and graphs were performed and made using
MATLAB software. Before simulation using the RL could take place, the learning phase
to determine the optimal parameter values associated with each control-relevant K value
had to be performed, and the results were as follows:

TABLE 2
PARAMETER VALUES
K
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

0
0
0
0
0
0
0
0
0

a
-3.00367
-2.25922
-0.82387
-0.4069
-0.58846
-0.26811
-0.25454
-0.1582
-0.19254

c
0.607573
0.562711
0.813361
0.737377
0.699238
0.564213
0.571812
0.503708
0.446211

f
0.413057
0.737318
0.573093
0.057894
0.835709
0.123133
0.274075
0.154036
0.232318

h
-3.79183
-3.35005
-3.47947
-4.13071
-3.10336
-4.27049
-4.01829
-4.37039
-4.13157

4.407258
4.774702
4.598232
3.924247
4.885482
3.988894
4.225859
3.982359
4.19317

The control relevant K values are listed in the first column of TABLE 2, and the
remaining columns list the parameter values associated with the control relevant K value
in the same row. The values for parameter “a” trended towards 0 as the control relevant
K value increased. When the values for parameter “a” were looked at in the context of
equation (6), it indicated that when the patient became more responsive to the warfarin
dose (control relevant K value increased), the same

values would result in a

smaller dose change. This means that if a patient was determined to have a high control
relevant K value, a smaller dose change is necessary to achieve the desired effect.
20

The results for parameter value “c” varied, which indicated that

had a

varying effect depending on the responder type. The parameter values for “ ”, when
taken in context of equation (7), were determined to be the optimal times between INR
measurements when the

and

values were both 0, which would mean the

patient had reached the target values for

and

both “f” and “h” varied, which indicated that the values for

. The parameter values for
and

had

varying effects depending on the control relevant K value, respectively, when taken in the
context of equation (7).
The first simulation was performed using only the RL algorithm in the presence
of no intra-patient variability (CV = 0%) and the results were as follows:

TABLE 3
SIMULATION 1 RESULTS

Simulation
1

Dosing
Algorithm
RL

CV
0%

%TTR
92.1%

%TTR standard
deviation
4.2%

mean # of INR
Measurements
7.94/patient

The first simulation, represented in TABLE 3, yielded a mean %TTR = 92.1% over all
100 artificial patients, with a standard deviation of 4.2%, and had a mean number of INR
measurements = 7.94 measurements/patient. These results indicated, that in the presence
of no intra-patient variability, the RL algorithm did an exceptional job of keeping the
simulated patients’ INR values within the therapeutic range. The reason the RL
algorithm was not able to attain a higher %TTR was due to 2 factors. First, each patient
started off with an INR value of 1, meaning that there was always a time when the
patient’s INR values were not in therapeutic range. Second, the initial dose given to the
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patient was 5mg/day (the American Society of Hematology recommended starting dose
(Cushman, Lim, & Zakai, 2011)), which, in the cases of the medium and hyper responder
types (see FIGURES 3 and 4), can cause an overshoot of the therapeutic range due to an
incorrect initial dose and not due to controller action. FIGURES 2, 3, and 4 are sample
plots of the results that were attained from single patient types (hypo, medium, and hyper
responders). A comparison to the current standard of care was still necessary to prove
that the RL algorithm was viable.

FIGURE 2 - Sample plot of a single patient - Hypo-Responder. The top plot is the
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic
range. The bottom plot is the dose.
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FIGURE 3 - Sample plot of a single patient - Medium-Responder. The top plot is the
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic
range. The bottom plot is the dose.
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FIGURE 4 - Sample plot of a single patient - Hyper-Responder. The top plot is the
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic
range. The bottom plot is the dose.

The second simulation was performed with all 100 artificial patients using the
American Society of Hematology dosing algorithm (represented as ASH in TABLE 4),
which is the current standard of care, and the third simulation was performed with all 100
artificial patients using the warfarin RL algorithm (indicated in TABLE 4 as RL).
Simulations two and three were both performed in the presence of heavy intra-patient
variability (CV = 25%) and the results were as follows:
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TABLE 4
SIMULATIONS 2 AND 3 RESULTS

Dosing
Simulation Algorithm
2
ASH
3
RL

CV
25%
25%

%TTR
standard
deviation
16.4%
10.8%

%TTR
45.3%
51.8%

mean # of INR
Measurements
12.30/patient
8.05/patient

RL vs
ASH
pvalue
<.001

The second simulation, represented in TABLE 4, yielded a mean %TTR = 45.3%
over all 100 artificial patients, with a standard deviation of 16.4%, and had a mean
number of INR measurements = 12.3 measurements/patient. The third simulation,
represented in TABLE 4, yielded a mean %TTR = 51.8% over all 100 artificial patients,
with a standard deviation of 10.8%, and had a mean number of INR measurements = 8.05
measurements/patient. There was determined to be a statistically significant difference
(P<.001) between the American Society of Hematology algorithm and the warfarin RL
algorithm. Figures 5, 6, and 7 are sample plots of the results that were attained from
single patient types (hypo, medium, and hyper responders).
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FIGURE 5 - Sample plot of a single patient - Hypo-Responder. The top plot is the
patient’s INR response using the RL algorithm, where the blue line is INR and the red
lines indicate therapeutic range. The bottom plot is the patient’s INR response using the
ASH algorithm.
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FIGURE 6 - Sample plot of a single patient - Medium-Responder. The top plot is the
patient’s INR response using the RL algorithm, where the blue line is INR and the red
lines indicate therapeutic range. The bottom plot is the patient’s INR response using the
ASH algorithm.
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FIGURE 7 - Sample plot of a single patient - Hyper-Responder. The top plot is the
patient’s INR response using the RL algorithm, where the blue line is INR and the red
lines indicate therapeutic range. The bottom plot is the patient’s INR response using the
ASH algorithm.

The results listed in TABLE 4 indicated that the warfarin RL algorithm not only
did a better job at keeping the patient’s INR in therapeutic range, but also reduced the
number of INR measurements that were required per patient. When translated into a real
world scenario, the data from TABLE 4 indicated that the warfarin RL algorithm would
result in greater patient safety and therapeutic efficacy by keeping the patient’s INR
values in therapeutic range for a greater amount of time than the current standard of care.
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The warfarin RL algorithm was also able to reduce the mean number of INR
measurements that were necessary over all 100 artificial patients, which indicated that the
overall cost of the warfarin therapy when using the warfarin RL algorithm would be less
than the cost of warfarin therapy when using current standard of care.
The %TTR values listed in TABLE 4 correspond closely with %TTR values that
are typically seen in clinical practice (Wilson, Costantini, & Crowther, 2007). The
warfarin RL algorithm performed better than the current standard of care (ASH
algorithm) at keeping patient’s INR values in the therapeutic range due to its ability to
switch between controllers to match each patient’s response instead of slowly titrating the
dose until the desired effect is achieved. When a patient is matched to their respective
control relevant K value, the algorithm is able to make smaller or larger dose changes to
match the possible patient response, whereas the ASH algorithm uses titration to achieve
the desired INR value. This means that the warfarin RL algorithm is able to respond
faster and better when a patient’s response to warfarin dose changes, which can occur due
to intra-patient variability factors (diet, drug interactions, and disease state), than titration
based algorithms.
The mean number of INR measurements that were necessary, listed in TABLE 4,
are another important factor to consider when comparing the warfarin RL algorithm with
the current standard of care. As previously stated, utilizing the warfarin RL algorithm
resulted in a fewer number if INR measurements that were necessary when compared to
the current standard of care, and that would result in a reduction of the overall cost of the
therapy. The rising cost of healthcare and the uncertain changes that are occurring in the
U.S. healthcare market are important considerations when evaluating this metric. If a
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patient could receive superior healthcare at a lower cost, the patient would be, overall,
more satisfied. Also, the cost of warfarin therapy is more than just monetary, and patient
convenience is an important factor to consider. If fewer INR measurements were
necessary over the course of warfarin therapy, this would greatly increase patient
convenience and quality of life.
Drug dosing as a whole, even outside of the realm of warfarin and anticoagulants,
could greatly benefit from the use of engineering methods like the one presented in this
study. For most drugs, outdated dosing methodologies are used to slowly titrate the dose
until a desirable effect is achieved. These methodologies can be inefficient, and can even
have the potential to be dangerous if the proper dose is not determined fast enough or the
methodology used is slow to respond to inter and intra patient variability. There is a need
for the development of new dosing methodologies that utilize engineering methods to
improve patient safety, and reduce the cost of different types of therapy by more
“intelligently” dosing patients.
These methods could be applied to drugs like Plavix, which is an antiplatelet
agent, and also other unrelated drugs such as erythropoiesis stimulating agents, which are
used to stimulate red blood cell production in patients with End Stage Renal Disease. In
fact, there is evidence in the literature which suggests that control systems engineering
methodologies have been effective in real life clinical settings (Gaweda, Jacobs, Arnoff,
& Brier, 2008). If the medical community were to develop and adopt “smarter” dosing
protocols based on control systems engineering techniques, patient’s receiving a variety
of different drug therapies would benefit greatly.
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VII. CONCLUSIONS

Based on the data from the simulations that were performed, the patient
population as a whole could greatly benefit from using the RL warfarin algorithm as an
alternative to the current standard of care. Using the RL warfarin algorithm could help
keep patient’s INR in therapeutic range in the presence of heavy intra-patient variability
while also greatly reduce the cost of the therapy by optimizing the number of INR
measurements that are required. The RL Warfarin Algorithm offers distinct advantages
compared to the industry standard dosing methods, and while there are other
computational and evidence based algorithms in practice, no other algorithm optimizes
monitoring frequency. Next, a human study of the RL warfarin algorithm should be
performed to ensure patient safety and efficacy.
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